Lupin, AbbVie To Develop Novel Oncology Drug To Treat Hematological Cancers

Tablet displaying intraday stock performance

(RTTNews.com) - Lupin Limited and AbbVie Inc. (ABBV) said that AbbVie has licensed Lupin's MALT1 or Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 inhibitor program.

Under the partnership, AbbVie gains exclusive global rights to develop and commercialize Lupin's MALT1 inhibitors. MALT-1 is a protein involved in T-cell and B-cell lymphocyte activation and AbbVie intends to pursue development across a range of hematological cancers, many with limited current treatment options.

As per the terms of the agreement, AbbVie will pay Lupin an upfront payment of US$30 million for an exclusive license to the program. Upon successful completion of regulatory, development and commercial milestones, Lupin is eligible to receive total milestone payments of up to US$947 million.

Additionally, Lupin will be entitled to receive a double-digit royalty on the sales of the product and will retain commercial rights to the program in India.

Read the original article on RTTNews (http://www.rttnews.com/2965248/lupin-abbvie-to-develop-novel-oncology-drug-to-treat-hematological-cancers.aspx)

For comments and feedback: contact editorial@rttnews.com


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.